Endometrioid endometrial cancer - The prognostic value of selected clinical and pathological parameters;Gruczolakorak endometrium typu endometrioidalnego - Analiza wartości prognostycznej wybranych parametrów klinicznych i histopatologicznych

Ginekologia Polska

Volumn 82, Issue 10, 2011, Pages 743-748

  Leszek, Gottwald ^a,b   Justyna, Chałubińska ^b   Małgorzata, Moszyńska Zielińska ^b   Janusz, Piekarski ^a   Wiesław, Tyliński ^a   Jarosław, Szwalski ^b   Robert, Kubiak ^a   Grazyna, Pasz Walczak ^a   Katarzyna, Hendzel ^b   Aleksandra, Ciałkowska Rysz ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Wojewódzki Specjalistyczny Szpital im M Kopernika ^*  (Poland)

Author keywords

Endometrial adenocarcinoma; Endometrioid carcinoma; Overall survival; Prognostic factors; Relapse

Indexed keywords

EID: 80955123474     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Zakład Epidemiologii i Prewencji Nowotworów Centrum Onkologii - Instytut w Warszawie. Krajowa baza danych nowotworowych. http://www.onkologia.org.pl
2. Benedet J, Bender H, Jones H 3 rd, [et al.]. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000, 70, 209-262.
3. Sonoda Y, Barakat R. Screening and the prevention of gynecologic cancer: endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2006, 20, 363-377.
4. Sivridis E, Giatromanolaki A. Endometrial adenocarcinoma: an apostasy from early views. Gynecol Oncol. 2004, 95, 772-777.
5. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol. 1991, 41, 1-16.
6. Purdie D, Green A. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001, 15, 341-354.
7. Voigt L, Weiss N. Epidemiology of endometrial cancer. Cancer Treat Res. 1989, 49, 1-21.
8. Steinbakk A, Gudlaugsson E, Aasprong O, [et al.]. Molecular biomarkers in endometrial hyperplasias predict cancer progression. Am J Obstet Gynecol. 2011, 204, 357.e1-12.
9. Querleu D, Planchamp F, Narducci F, [et al.]. Clinical practice guidelines for the management of patients with endometrial cancer in France: Recommendations of the Institut National du Cancer and the Société Française d'Oncologie Gynécologique. Int J Gynecol Cancer. 2011, 21, 945-950.
10. Pecorelli S, Denny L, Ngan H, [et al.]. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol Oncol. 2009, 115,:325-328.
11. Engelsen I, Akslen L, Salvesen H. Biologic markers in endometrial cancer treatment. APMIS. 2009, 117, 693-707.
12. Uharcek P, Mlyncek M, Ravinger J, Matejka M. Prognostic factors in women 45 years of age or younger with endometrial cancer. Int J Gynecol Cancer. 2008, 18, 324-328.
13. Yoney A, Yildirim C, Isikli L, Unsal M. Prognostic factors and treatment outcomes in patients with operated endometrial cancer: analysis of 674 patients at a single institution. J BUON. 2011, 16, 64-73.
14. Cirisano F, Robboy S, Dodge R, [et al.]. Epidemiopathologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol. 1999, 74, 385-394.
15. Steiner E, Eicher O, Sagemüller J, [et al.]. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer. 2003, 13, 197-203.
16. Jolly S, Vargas C, Kumar T, [et al.]. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation. Gynecol Oncol. 2006, 103, 87-93.
17. Labastida R, Dexeus S, Fábregas R, [et al.]. Endometrial cancer: factors affecting survival. Eur J Gynaecol Oncol. 2003, 24, 381-383.
18. Alektiar K, McKee A, Lin O, [et al.]. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002, 54, 79-85.
19. Esselen K, Boruta D, Del Carmen M, [et al.]. Defining prognostic variables in recurrent endometrioid endometrial cancer: A 15-year single-institution review. Int J Gynecol Cancer. 2011, 21, 1078-1083.
20. Steiner E, Schmidt M, Weikel W, Koelbl H. Influence of diabetes mellitus and nodal distribution in endometrial cancer and correlation to clinico-pathological prognostic factors. Eur J Gynaecol Oncol. 2006, 27, 477-480.
21. Fung-Kee-Fung M, Dodge J, Elit L, [et al.]. Follow-up after primary therapy for endometrial cancer. a systematic review. Gynecol Oncol. 2006, 101, 520-529.
22. Sartori E, Laface B, Gadducci A, [et al.]. Factors influencing survival in endometrial cancer relapsing patients: a Cooperation Task Force (CTF) study. Int J Gynecol Cancer. 2003, 13, 458-465.
23. Hirai M, Hirono M, Oosaki T, [et al.]. Prognostic factors relating to survival in uterine endometrioid carcinoma. Int J Gynecol Obstet. 1999, 66, 155-162.
24. Creutzberg C, van Putten W, Koper P, [et al.]. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003, 89, 201-209.
25. Carey M, Gawlik C, Fung-Kee-Fung M, [et al.]. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol. 2006, 101, 158-167.
26. Steiner E, Plata K, Interthal C, [et al.]. Diabetes mellitus is a multivariate independent prognostic factor in endometrial carcinoma: a clinicopathologic study on 313 patients. Eur J Gynaecol Oncol. 2007, 28, 95-97.
27. Boll D, Verhoeven R, van der Aa M, [et al.]. Adherence to national guidelines for treatment and outcome of endometrial cancer stage I in relation to co-morbidity in southern Netherlands 1995-2008. Eur J Cancer. 2011, 47, 1504-2510.